Title:
ANTI-CD39 ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/051712
Kind Code:
A1
Abstract:
Provided are an anti-CD39 antibody-drug conjugate or a pharmaceutically acceptable salt or solvent compound thereof, a pharmaceutical composition comprising the conjugate or the pharmaceutically acceptable salt or solvent compound thereof, and a use thereof as an anti-cancer drug, and in particular, a use in the preparation of drugs for treating CD39-mediated diseases or symptoms. The anti-CD39 antibody-drug conjugate provided significantly improves the effect of cytotoxin drugs and in vivo and in vitro tumor-killing activity.
Inventors:
LI ZHAOHUI (CN)
WU MIN (CN)
ZHANG QIAN (CN)
XIE ZHANGMING (CN)
FANG HEDI (CN)
FANG JIE (CN)
LIU WENHUI (CN)
LIU WENHUI (CN)
LIU LIXU (CN)
LV YUBIN (CN)
WU MIN (CN)
ZHANG QIAN (CN)
XIE ZHANGMING (CN)
FANG HEDI (CN)
FANG JIE (CN)
LIU WENHUI (CN)
LIU WENHUI (CN)
LIU LIXU (CN)
LV YUBIN (CN)
Application Number:
PCT/CN2022/122682
Publication Date:
April 06, 2023
Filing Date:
September 29, 2022
Export Citation:
Assignee:
HANGZHOU BIOSUN PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61P35/00
Domestic Patent References:
| WO2021088838A1 | 2021-05-14 | |||
| WO2021030251A1 | 2021-02-18 |
Foreign References:
| US20170335007A1 | 2017-11-23 | |||
| CN112839675A | 2021-05-25 | |||
| CN111372606A | 2020-07-03 | |||
| CN112262155A | 2021-01-22 |
Other References:
SPATOLA, B. N. ET AL.: "Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism.", MABS., vol. 12, no. 1, 4 November 2020 (2020-11-04), XP055825366, DOI: 10.1080/19420862.2020.1838036
Attorney, Agent or Firm:
SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM (CN)
Download PDF: